Differential diagnosis points to possible congenital case of linear atrophoderma in nine-month-old patient
Washington, D.C. - Of the approximately 19 cases of linear atrophoderma of Moulin described in the literature; all of them presented in children or young adults less than 20 years of age -- until, perhaps, now. Gina C. Ang, M.D., and colleagues at Philadelphia's Jefferson Medical College, may have identified the first case of congenital linear atrophoderma, or at least the first one to come to the attention of the medical community.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.